Citizenship Israeli and American Name Arie Belldegrun Years active 1988-present Role Businessman | Religion Jewish Children 4 | |
 | ||
Born 1949 (age 65–66) Israel Alma mater Hadassah Medical CenterWeizmann Institute of Science Residence Los Angeles, California, United States | ||
Ucla researcher dr arie belldegrun on kidney cancer
Arie S. Belldegrun (born 1949) is an Israeli-born American urologic oncologist, businessman, and investor.
Contents
- Ucla researcher dr arie belldegrun on kidney cancer
- Arie Belldegrun Keynote Yale Innovation Summit 2018
- Early life and academia
- Agensys
- Cougar Biotechnology
- Two River
- Kite Pharma
- Other board memberships
- Recent business
- Personal life
- References
Arie Belldegrun Keynote Yale Innovation Summit 2018
Early life and academia
Belldegrun was born in Israel. He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979. He completed his Urologic Surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988. He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Belldegrun is the Director of the UCLA Institute of Urologic Oncology, Professor of Urology, and Chief of the Division of Urologic Oncology at the David Geffen School of Medicine.
Agensys
In 1996, Belldegrun established Agensys, an early-stage privately held biotechnology company based in Los Angeles, that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. He served as its founding Chairman of the Board of Directors from 1996 to 2002, and then as a Director until December 2007, when Agensys was acquired by Astellas Pharma in a deal valued at $537 million.
Cougar Biotechnology
Belldegrun has been a founding Vice Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology since 2003, a Los Angeles-based company with a focus in the field of oncology. In July 2009, the company was acquired by Johnson & Johnson in a $970 million transaction. In April 2011, the United States Food and Drug Administration approved Abiraterone Acetate (Zytiga), Cougar’s lead product, for late stage prostate cancer.
Two River
Since 2008, Belldegrun has been the Chairman and Partner of Two River, a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventative and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.
Kite Pharma
Belldegrun is the Chairman, President and CEO of Kite Pharma (NASDAQ: KITE) which he founded in 2009. Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products with a primary focus on engineered autologous T cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. The company went public in June 2014. Belldegrun, who owns 6.38 million shares of the company, has a stake worth over $400 million today. On August 28, 2017, the biopharmaceutical firm Gilead to buy the Israeli-founded Kite Pharma for nearly $12 billion USD an all-cash deal.
Other board memberships
Belldegrun also serves as a member of the following boards:
In the past, Belldegrun served as a member of a number of boards, including:
Recent business
Personal life
Belldegrun is married to Dr. Rebecka Belldegrun and together they have four children. They reside in Bel Air, an affluent neighborhood in Los Angeles. Their oldest son, Ben Belldegrun, a hedge fund manager, is married to Kelly Bergantz, senior producer for Syco.
In 2014, according to the Bloomberg Pay Index, Belldegrun was ranked the 8th highest-paid executive in the United States, with a pay package valued at $95.2 million.
In 2015, The Hollywood Reporter's annual Hollywood's Top Doctors list included Belldegrun as one of the highest-rated urologists.
In 2016, in its annual ranking of the wealthiest people in Israel, Forbes Israel ranked Arie and Rebecka Belldegrun 37th with a personal net worth of ₪3.9 billion (equal to US$1 billion).
Belldegrun has written over 400 scientific publications related to urologic oncology, and has authored several books on prostate and kidney cancers. He was one of the speakers at the Milken Institute Global Conference 2013, delivered the keynote Andrew C. Novick Memorial Lecture at the Ninth International Kidney Cancer Symposium, and regularly presents at the Annual J.P. Morgan Healthcare Conference. It was announced that Belldegrun will present at the 34th Annual J.P. Morgan Healthcare Conference in January 2016.
Arie and Rebecka Belldegrun have donated over $1 million to the University of Pennsylvania School of Arts and Sciences, and have donated a $5 million sculpture to LACMA.